171 related articles for article (PubMed ID: 34757213)
1. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
von Moos R; Lewis K; Massey L; Marongiu A; Rider A; Seesaghur A
Bone; 2022 Jan; 154():116243. PubMed ID: 34757213
[TBL] [Abstract][Full Text] [Related]
2. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
[TBL] [Abstract][Full Text] [Related]
3. Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital.
Seesaghur A; Egger P; Warden J; Abbasi A; Levick B; Riaz M; McMahon P; Thompson M; Cheeseman S
BMJ Open; 2023 May; 13(5):e069214. PubMed ID: 37156580
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
[TBL] [Abstract][Full Text] [Related]
6. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
Link H; Diel I; Ohlmann CH; Holtmann L; Kerkmann M;
Support Care Cancer; 2020 May; 28(5):2175-2184. PubMed ID: 31410600
[TBL] [Abstract][Full Text] [Related]
7. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
[TBL] [Abstract][Full Text] [Related]
8. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
Jakob A; Zahn MO; Nusch A; Werner T; Schnell R; Frank M; Hamm N; Däßler KU; Losem C; Welslau M; Hoevel P; Potthoff K
J Bone Oncol; 2022 Apr; 33():100420. PubMed ID: 35340302
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
[TBL] [Abstract][Full Text] [Related]
10. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
12. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
[TBL] [Abstract][Full Text] [Related]
16. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
17. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
18. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
20. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
von Moos R; Body JJ; Egerdie B; Stopeck A; Brown JE; Damyanov D; Fallowfield LJ; Marx G; Cleeland CS; Patrick DL; Palazzo FG; Qian Y; Braun A; Chung K
Support Care Cancer; 2013 Dec; 21(12):3497-507. PubMed ID: 23975226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]